 James Lee, MD
|
| Title | CLINICAL FELLOW |
|---|
| School | UCSF School of Medicine |
|---|
| Department | Medicine |
|---|
| Address | 505 Parnassus Avenue
San Francisco CA 94117
|
|---|
| vCard | Download vCard |
|---|
|
|
 Biography | 2006
-
| 2007 | American Medical Association Seed Grant | | 2006
-
| 2007 | American Society of Hematology Trainee Award | | 2007
-
| 2008 | Farr Scholar Award for Leadership and Excellence in Biomedical Research, Yale University | | 2008
-
| 2009 | American Cancer Society of Connecticut Research Award | | 2016
-
| 2017 | NIH Immunology T32 | | 2017
-
| 2019 | A.P. Giannini Fellowship Award |
Overview I am a hematology/oncology fellow with significant research experience in adoptive T cell therapy using chimeric antigen receptors (CARs). My current focus is on the design of next generation CARs for more effective therapy in the setting of a tolerant/suppressive tumor microenvironment in solid malignancies.
Translating recent advancements in cellular cancer immunotherapy to metastatic solid tumors has been especially challenging, and this is highlighted by the lack clinical response outside of the CD19 ideal antigen as target. Current forms of therapy is likely insufficient to overcome the naturally tolerogenic microenvironment evolved to protect against autoimmunity. Using the liver as a model organ of immune tolerance, I intend to study the mechanism of tumor escape in the setting of checkpoint inhibition and adoptive T cell therapy.
My hope is to see cellular immunotherapy become a mainstream form of cancer treatment.
Professional Experience:
Clinical Instructor, Memorial Sloan-Kettering Cancer Center, New York, NY. July 2012-July 2013
Clinical Instructor, University of California, San Francisco, CA. July 2013-July 2014
Education:
Medical School: Yale School of Medicine, New Haven, CT. September 2003-May 2009
Research Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY. 2006-2009.
Residency: Mount Sinai Medical Center, New York, NY. July 2009-June 2012
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Researchers can login to make corrections and additions, or contact us for help.
-
Holohan DR, Lee J, Bluestone JA. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-2. PMID: 26461084.
-
Lee J, Pegram HJ*, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 18(119):4133-41.
-
Lee J, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011 Apr 15; 71(8):2871-81. PMID: 21487038; PMCID: PMC3094720.
-
Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M, Brentjens RJ. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 2009 Mar; 15(3):338-44. PMID: 19219023; PMCID: PMC2837150.
-
Lee J, Sadelain M, Brentjens R. Retroviral transduction of murine primary T lymphocytes. Methods Mol Biol. 2009; 506:83-96. PMID: 19110621.
-
Inventing New CARs: Analysis of Chimeric Antigen Receptor Gene-Targeted T cells Modified to Overcome Regulatory T cell Suppression in the Tumor Microenvironment. Yale University MD Thesis. 2009.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Related Authors People who share related concepts with this person. _
|
